Prevention & lipidsCohort study
Risk of major cardiovascular events and all-cause death in patients with bronchiectasis and associated resistance to antimicrobial drugs
- Retrospective cohort study
- propensity-score matched
- TriNetX research network
Authors' conclusion
In patients with bronchiectasis, AMR is associated with an increased risk of MACE and all-cause death
Study context
- Population
- Patients with bronchiectasis1:1 propensity score matching (PSM)
- Participants
- 6,543 vs 154,685
- Exposure
- Antimicrobial resistance (AMR) vs no AMR
- AMRn = 6,543
- Non-AMRn = 154,685reference
- Outcome
- MACE (MI, stroke, systemic thromboembolism, cardiac arrest) and all-cause death
Main finding
As reported in the abstract
AMR vs Non-AMRHazard ratio (95% CI)
MACE
1.29(1.17–1.41)
all-cause death
1.49(1.38–1.61)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| MACE, no prior CV events (subgroup) | 1.56 (1.34–1.81) | |
| MACE, by cystic fibrosis status (subgroup) — AMR vs Non-AMR · cystic fibrosis | 1.24 (0.86–1.78) | |
| MACE, by cystic fibrosis status (subgroup) — AMR vs Non-AMR · non-cystic fibrosis | 1.28 (1.16–1.41) | |
| 0.512Hazard ratio (log scale) |
Major adverse cardiovascular event (MACE), by cystic fibrosis status (subgroup)
- Consistent findings across different AMR types
Original publication
Risk of major cardiovascular events and all-cause death in patients with bronchiectasis and associated resistance to antimicrobial drugs. Eur J Prev Cardiol. Published 4 March 2025. doi:10.1093/eurjpc/zwaf122
Summarised from the published abstract; every number is checked against it